Startups supported by Venture Kick have made remarkable achievements, with 66 Venture Kick alumni recognized among the TOP 100 Swiss Startups 2024. And despite a difficult fundraising environment, the ...

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections ...

Recent startup challenges are offering new platforms for startups to showcase and advance their solutions. Elythor and Prometheus are competing for a €100,000 grand prize in the HelloTomorrow ...

Yokoy, the leading spend management platform, has been acquired by TravelPerk, a business travel platform based in Barcelona. In parallel, TravelPerk announced the closing of a financing round in ...

Over the past two years, Voltiris has reached significant milestones, including 12 commercial projects with renowned growers in Europe, partnerships with leading energy utilities such as Elektra ...

AB2 Bio has entered into an option and licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company with extensive experience in marketing rare disease therapeutics in ...

Zurich-based ACP Advanced Circuit Pursuit AG, recognized for its robust IP portfolio and expertise in RF CMOS technology starts a new era as part of Paris-based Sequans Communications SA, a leading ...

Five Swiss startups are among the nine startups selected to join the second edition of the Digital Health Centre Bülach and Tenity. During four-months, participants will receive tailored support and ...

Swiss Organisations can now apply as Beneficiaries in Horizon Europe and Euratom calls from 2025 programme year onward. This event aims to provide valuable insights into the Swiss participation in ...

The panel of judges has nominated 11 startups from 45 submitted applications, for the ZKB Pioneerpreis Technopark 2024. The startups will proceed to the next stage as they contest to win a cheque for ...

There is currently no medication disease-modifying therapy available to treat BKV infection except for the lowering of immunosuppression. Memo Therapeutics’ lead candidate AntiBVK, is a highly ...

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised 7.5 Million CHF from existing ...